IGM Biosciences Liabilities 2024

IGM Biosciences Aktienanalyse

What does IGM Biosciences do?

IGM Biosciences Inc was founded in 2010 in Mountain View, California. It is a biopharmaceutical company focused on the development and commercialization of immunotherapy products for the treatment of cancer. Their business model is based on the use of proprietary technology platform to produce high-quality and high-quantity antibody products. The company has different business areas including research and development, antibody production and testing, and marketing and distribution of their products. They offer a wide range of products such as monoclonal antibodies, multi-specific antibodies, and antibody constructs. Their history began with the development of their platform technology, which allows for the production of antibodies with modified properties. This has led to breakthrough products for the treatment of cancer. One of their main products is IGM-2323, a multi-specific antibody targeting solid tumors. It works by binding to two different targets on the cancer cell simultaneously and activating the immune system to destroy the cancer cell. Another important product is IGM-8444, an antibody construct targeting B-cell lymphomas. It has been designed to enhance the immune response to cancer cells by specifically binding to a surface protein on the cancer cells. IGM Biosciences Inc has also formed partnerships with other companies to collaborate on the development of new products. For example, they have partnered with GlaxoSmithKline (GSK) to develop a new class of multi-specific antibodies for the treatment of cancer. Overall, IGM Biosciences Inc has a strong track record and continues to have significant growth potential in the future. Their business model is based on leveraging their proprietary technology platform to develop innovative immunotherapy products for cancer. With a wide range of products and partnerships in the pipeline, it is likely that this company will continue to be successful in the future. IGM Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing IGM Biosciences's Liabilities

IGM Biosciences's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating IGM Biosciences's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing IGM Biosciences's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

IGM Biosciences's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in IGM Biosciences’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about IGM Biosciences stock

What is the level of liabilities of IGM Biosciences this year?

IGM Biosciences has a debt balance of 220.18 M USD this year.

What were the liabilities of IGM Biosciences compared to the previous year?

The liabilities of IGM Biosciences have increased by -2.66% dropped compared to the previous year.

What are the consequences of high debt for investors of IGM Biosciences?

High liabilities can pose a risk for investors of IGM Biosciences, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in IGM Biosciences?

Low liabilities mean that IGM Biosciences has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of IGM Biosciences affect the company?

An increase in liabilities of IGM Biosciences can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of IGM Biosciences affect the company?

A decrease in the liabilities of IGM Biosciences can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of IGM Biosciences?

Some factors that can influence the liabilities of IGM Biosciences include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of IGM Biosciences so important for investors?

The liabilities of IGM Biosciences are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can IGM Biosciences take to modify the liabilities?

To change its liabilities, IGM Biosciences can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does IGM Biosciences pay?

Over the past 12 months, IGM Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGM Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of IGM Biosciences?

The current dividend yield of IGM Biosciences is .

When does IGM Biosciences pay dividends?

IGM Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IGM Biosciences?

IGM Biosciences paid dividends every year for the past 0 years.

What is the dividend of IGM Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IGM Biosciences located?

IGM Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von IGM Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IGM Biosciences from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did IGM Biosciences pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of IGM Biosciences in the year 2023?

In the year 2023, IGM Biosciences distributed 0 USD as dividends.

In which currency does IGM Biosciences pay out the dividend?

The dividends of IGM Biosciences are distributed in USD.